Nuvectis Pharma, Inc. - Common Stock — Bilan (NASDAQ:NVCT) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Total de l'actif 20.41 M19.18 M18.61 M31.71 M Total du passif 6.19 M6.98 M8.89 M13.3 M Total des capitaux propres 14.22 M12.2 M9.71 M18.41 M Total du passif et des capitaux propres 20.41 M19.18 M18.61 M31.71 M Dette totale ———— Dette nette ————

Nouvelles

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

Notation de l’action Nuvectis Pharma réitérée à l’achat par H.C. Wainwright

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright maintient sa recommandation d’achat sur Nuvectis Pharma avec un objectif de 10$

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%

Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright

Nuvectis halts NXP800 development for ovarian cancer, shifts focus